Insilico Medicine (HKG: 3696) and Tenacia Biotechnology, a central nervous system (CNS) specialist, announced an expanded and deepened AI-driven drug discovery collaboration, building on their initial partnership established March 2025. The enhanced agreement leverages Insilico’s Pharma.AI generative platform to develop innovative small molecule inhibitors with blood-brain barrier (BBB) penetrability for challenging neurological disorders, with total transaction value reaching up to USD 94.75 million.
Pipeline Expansion: Successful collaboration template for additional CNS targets (Alzheimer’s, Parkinson’s, ALS) with shared BBB-penetrant chemistry learnings
Forward‑Looking Statements This brief contains forward‑looking statements regarding AI-generated molecule properties, preclinical candidate advancement, and milestone achievement for the Insilico-Tenacia expanded collaboration. Actual results may differ due to AI model validation challenges, BBB penetration translation from in silico to in vivo, and CNS clinical trial execution risks.-Fineline Info & Tech
